Regulated information

Forcyl® - a booming brand

Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs.

Sales momentum continues in Q3

Vétoquinol posted sales of €220.9 million for the first 9 months of 2012, up 6.2% compared to the same period last year.

Vétoquinol purchases ORSCO laboratoire vétérinaire

Lure (France), September 25, 2012 – Vétoquinol announces the purchase of the entire equity of Orsco Laboratoire Vétérinaire.

Vétoquinol returns to growth

Lure (France), 29 August 2012 – At its 29 August 2012 meeting, the Vétoquinol S.A. board of directors reviewed the Group results and approved the financial statements for the first six months of 2012.

Solid first half 2012 Sales

First half 2012 sales reached €146.8 million, up 5.1% over first half 2011.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2011 (french version)

The registration document of Vétoquinol relative to fiscal year 2011, including the annual financial report relative to fiscal year 2011, was registered with the Autorité des marchés financiers (“the AMF”) on April 20th, 2012.

Strong Revenue growth in the first quarter of 2012

Vétoquinol achieved Q1 2012 sales of €77.0 million, up 15.9% compared to Q1 2011.

2011 annual earnings

Lure (France), April 03, 2012 – The Vétoquinol Board Meeting of March 26, 2012 has reviewed the Group’s business and approved the 2011 financial statements.

Flevox® the new parasiticide for dogs and cats

Lure (France), 14 February 2012 – Vétoquinol launches Flevox®, the latest addition to its range of parasiticides. The new drug is based on fipronil, the molecule par excellence in the treatment of tick and flea infestations in pets.

2011, a year of transition

Lure (France), January 24, 2012 – In 2011, Vétoquinol achieved sales of €284.1 million, 0.7% up on the previous year and stable on a like-for-like basis.

Vétoquinol announces opening of its first decentralized R&D center in Canada

Vétoquinol to market and distribute Vetprofen in the United States

3rd quarter revenues confirm promise of
strong growth prospects for 2007

For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the
corresponding period in 2006.

Reports very good first half, confirming that 2007 performance is set to surpass targets

Presentation of Vétoquinol’s results for the first half of 2007

2007 Half year results

Rapport semestriel 2007 « narratif » (french)

Suite à la publication du 26 juillet dernier, Vétoquinol a réalisé au 1er semestre 2007 un
chiffre d’affaires de 111,1 M€ contre 98,4 M€ au cours de la même période de l’exercice
précédent, soit une progression de 12,9 %.
A cours de change et périmètre constants, la progression est de 10,1 %.

Business is strong in first-half of 2007 : + 12.9%

2007 Half year Financial Report

Vétoquinol creates a subsidiary in Portugal

2006 Financial Report

Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent.
Le résultat opérationnel courant, qui s’élève à 25,6 M€, est en augmentation de 10,8%.
Enfin, le résultat net de 15,8 M€ progresse de 27,2% et représente 7,5% du chiffre d’affaires.
Cette croissance a été maîtrisée et équilibrée.

Activity Report 2006

Annual earnings for 2006: a year of good performance

Présentation des résultats 2006 de Vétoquinol (french)

Vétoquinol reports one of its industry’ strongest growth performances in 2006

Sustained revenue growth in 2006

Vétoquinol strengthens its position in the United States